Context Therapeutics Inc
NASDAQ:CNTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Context Therapeutics Inc
Accrued Liabilities
Context Therapeutics Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Context Therapeutics Inc
NASDAQ:CNTX
|
Accrued Liabilities
$5.4m
|
CAGR 3-Years
35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accrued Liabilities
$32.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accrued Liabilities
$13.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Accrued Liabilities
$3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accrued Liabilities
$14.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accrued Liabilities
$19.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
Context Therapeutics Inc
Glance View
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. The company is headquartered in Philadelphia, Pennsylvania and currently employs 7 full-time employees. The company went IPO on 2021-10-20. The firm is engaged in developing small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The Company’s clinical program for lead candidate, onapristone extended release (ONA-XR), comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. ONA-XR is a small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Its second program, CLDN6xCD3, is an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody (bsAbs) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing Claudin 6 (CLDN6).
See Also
What is Context Therapeutics Inc's Accrued Liabilities?
Accrued Liabilities
5.4m
USD
Based on the financial report for Dec 31, 2025, Context Therapeutics Inc's Accrued Liabilities amounts to 5.4m USD.
What is Context Therapeutics Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 3Y
35%
Over the last year, the Accrued Liabilities growth was 336%. The average annual Accrued Liabilities growth rates for Context Therapeutics Inc have been 35% over the past three years .
